trastuzumab envedotin (DP303c) / CSPC Pharma - LARVOL DELTA

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors. (PubMed, NPJ Precis Oncol) - P1 | "Previous in vitro studies demonstrated that DP303c showed similar or better antitumor activity than T-DM1 in xenograft models. Based on safety and efficacy results, 3.0 mg/kg Q3W was determined as recommended phase 2 dose for DP303c. (Trial registration: ClinicalTrials.gov Identifier: NCT04146610)."

Journal • P1 data • Breast Cancer • Dry Eye Disease • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ophthalmology • Pain • Peripheral Neuropathic Pain • Solid Tumor • HER-2

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=252 | Not yet recruiting | Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd

New P1/2 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

SinoVac: HER2 ADC (DP303c injection) has entered the key phase III clinical stage [Google translation] (Eastmoney.com) - "...On August 4, the company said on the interactive platform that the ADC series of products are currently progressing smoothly and are in the clinical development stage. The HER2 ADC (DP303c injection) is progressing rapidly and has entered the critical Phase III clinical stage."

Trial status • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Shanghai Runshi Pharmaceutical Technology Co., Ltd.'s application for implied license for clinical trials of drugs has been accepted [Google translation] (163.com) - "On May 27, according to the official website of CDE, Shanghai Runshi Pharmaceutical Technology Co., Ltd. and Shanghai Institute of Materia Medica, Chinese Academy of Sciences jointly applied for the drug 'Ximetinib Hydrochloride Tablets' and obtained implicit clinical trial approval, acceptance number CXHL2400288....Ximetinib Hydrochloride Tablets combined with DP303c Injection are used to treat patients with previously treated HER2-expressing locally advanced/metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma."

New trial • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=442 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=442 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors (ESMO 2023) - P1 | "Pre-clinical study demonstrated similar to or better antitumor activity than T-DM1 in xenograft models. Conclusions DP303c demonstrated promising anti-tumor activity with acceptable safety in pts with pre-treated advanced solid tumors, especially BC. The pivotal phase II study in pts with BC is ongoing."

Clinical • Metastases • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

DP303c in Patients With HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=420 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study (AACR 2023) - "Background: SHR-A1811 is an ADC comprised of a humanized anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a DNA topoisomerase I inhibitor payload. SHR-A1811 was well-tolerated and showed promising antitumor activity in heavily pretreated advanced solid tumors.Table 1. Subgroup analyses of ORRNo. of prior treatment lines in metastatic setting in all pts (N=250)HER2 positive BC (N=108)HER2-low BC (N=77)Other tumor types (N=65)≤381.8% (45/55)58.7% (27/46)36.7% (18/49)>381.1% (43/53)51.6% (16/31)31.3% (5/16)Prior anti-HER2 therapies in pts with BC (N=185)*HER2 positive BC (N=108)HER2-low BC (N=77)All BC (N=185)Any82.2% (88/107, 73.7-89.0)68.8% (11/16, 41.3-89.0)80.5% (99/123, 72.4-87.1)Trastuzumab81.9% (86/105, 73.2-88.7)75.0% (9/12, 42.8-94.5)81.2% (95/117, 72.9-87.8)Pertuzumab83.0% (39/47, 69.2-92.4)100% (5/5, 47.8-100)84.6% (44/52, 71.9-93.1)Pyrotinib86.9% (53/61, 75.8-94.1)71.4% (5/7, 29.0-96.3)85.3% (58/68, 74.6-92.7)Lapatinib80.0% (28/35,..."

Clinical • Metastases • P1 data • PK/PD data • Biliary Cancer • Biliary Tract Cancer • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer • HER-2

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index. (PubMed, Onco Targets Ther) - "DP303c demonstrated remarkable anticancer efficacy against T-DM1 in xenograft models. DP303c was a strong candidate for the treatment of patients with HER2-positive cancer."

Journal • Oncology

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer (clinicaltrials.gov) - P2 | N=191 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor